TrialRadiation oncology (London, England)2019

Mono-institutional phase 2 study of innovative Stereotactic Body RadioTherapy targeting PArtial Tumor HYpoxic (SBRT-PATHY) clonogenic cells in unresectable bulky non-small cell lung cancer: profound non-targeted effects by sparing peri-tumoral immune microenvironment.

Slavisa Tubin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.